Clinical Trial Partnership Strategy can utilize a multitude of resources and skills to accomplish this trial.
Peter Lobel Ph. D - Therapeutic Investigator Robert Wood Johnson Med School 679 Hoes Lane Piscataway, NJ. 08854 Evan Snyder M.D., Ph. D - Therapeutic Investigator Assistant Professor of Neurology - Harvard 300 Longwood Ave. CH- Enders 248 Boston, MA. 02115 William Mobley M.D., Ph. D - Therapeutic Investigator Stanford University School of Medicine Department of Neurology SUMC H3160 Stanford, CA. 94305-5235 David Sleat Ph. D.- Therapeutic Investigator Center for Advanced Biotechnology and Medicine 675 Hoes Lane Piscataway, NJ. 08854 Jonathan Cooper Ph. D - Therapeutic Investigator Stanford University School of Medicine Department of Neurology SUMC H3160 Stanford, CA. 94305-5235 Martin Katz Ph. D. - Therapeutic Investigator University of Missouri One Hospital Drive Columbia, MO. 65212 Sandra L. Hofmann, M.D., Ph. D. - Therapeutic Investigator Southwestern Medical Center Department of Internal Medicine University of Texas 5323 Harry Hines Blvd. Dallas, TX. 75235-8593 The research effort for this clinical trial has a scientific advisory board. Key members of this board is: Michael Blaese MD - Advisor 300 Pheasant Run Newtown PA. 18940 Rose-Mary Boustany MD - Advisor/Clinician Duke University Medical Center MSRB Box 2604 Research Drive Durham, NC. 27710
CLN1/CLN2 – 39 Million LSDs – 242 Million Metabolic Disorders 2.5 Billion
The United States, Canada, Japan, China, Australia, and each country in Europe are included in the revenue forecast projections 50K per treatment is relatively conservative. Compare other life saving procedures (heart transplant….)
$39 Million dollar Market
Being on the leading edge of science will separate your organization from all the others. We can test mice and monkeys forever but we still will not be able to answer questions about humans. It is time to validate science.